Delivery of repurposed disulfiram by aminated mesoporous silica nanoparticles for anticancer therapy

• Published in: Journal of molecular liquids 2022-01, Vol.346, p.117065, Article 117065
• Main Authors: Aquib, Md, Zhang, Hang, Raza, Faisal, Banerjee, Parikshit, Bavi, Rohit, Kesse, Samuel, Boakye-Yiadom, Kofi Oti, Filli, Mensura Sied, Farooq, Muhammad Asim, Wang, Bo
• Format: Article
• Language: English
• Subjects: Aminated mesoporous silica nanoparticles; Cancer; Disulfiram; Drug delivery; Repurposed drug
• ISSN: 0167-7322
• DOI: 10.1016/j.molliq.2021.117065

[Display omitted] •AMPSNP fabricated by co-condensation method for the delivery of DSF against cancer.•AMPSNP demonstrated high drug loading, solubility, and pH-responsive drug release.•The DSF-AMPSNP showed enhanced cytotoxicity and cellular uptake against A549 cells.•The DSF-AMPSNP formulation exhibited effective anticancer effects in vivo. Herein, aminated mesoporous silica nanoparticles (AMPSNPs) were developed by using the co-condensation process and were further explored as a nanocarrier for disulfiram (DSF) delivery, which is classified as a “repurposed drug” for a variety of cancer therapies. The optimized DSF loading and encapsulation efficiency were found to be 18.05 ± 0.62% and 93.01 ± 0.83%, respectively. The scanning electron microscopy (SEM) showed a spherical and uniform formation of optimized AMPSNPs. Transmission electron microscopy (TEM) clearly displayed that the developed silica nanoparticles (NPs) contain mesostructures in them. For discovering a successful formation of an anticancer drug delivery system, various physicochemical characterization techniques were studied, such as PXRD, DSC, and FTIR. Hemolysis study revealed a better blood compatibility of the synthesized AMPSNPs. Furthermore, in vitro cellular cytotoxicity assay displayed an excellent cytotoxic profile of DSF-AMPSMPs compared to that of free DSF. Additionally, in vivo anti-tumor study conducted on A549 tumor-bearing nude mice verified a substantial tumor volume suppression and greater tumor growth inhibition with DSF-AMPSNP treatment group compared to using blank-AMPSNP and the free DSF group, with limited adverse-effects on mice health. Thus, we fervently have confidence that the AMPSNP could be utilized as a capable drug carrier for the delivery of DSF in cancer therapies.